Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
COVID-19
Yale
Questions discussed in this category
Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?
I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...
3 Answers available
How has COVID-19 altered your recommendations for invasive mediastinal staging for NSCLC?
Should staging and treatment decisions be made based on imaging alone?
2 Answers available
Should we consider deferring adjuvant chemotherapy for resected early-stage NSCLC in light of COVID-19?
If so, how long is too long to wait?
1 Answer available
6891
6816
6815
Related Topics in COVID-19
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Oncology
Gastrointestinal Cancers
Genitourinary Cancers
Melanoma/Skin Cancer
Non-malignant Disease
Pediatric Hematology/Oncology